Diabetes Endpoints: A1C Reduction Is ‘Still Enough,’ Just Not For Lexicon’s Sotagliflozin, US FDA Says

 
• By Sue Sutter
  
Is the FDA moving the regulatory goalposts for sotagliflozin by searching for benefits beyond reduction in hemoglobin A1C? (Shutterstock)

More from US Advisory Committees

More from Pathways & Standards